Discovery of highly selective and orally available benzimidazole-based phosphodiesterase 10 inhibitors with improved solubility and pharmacokinetic properties for treatment of pulmonary arterial hypertension.

Optimization efforts were devoted to discover novel PDE10A inhibitors in order to improve solubility and pharmacokinetics properties for a long-term therapy against pulmonary arterial hypertension (PAH) starting from the previously synthesized inhibitor A. As a result, a potent and highly selective PDE10A inhibitor, 14· 3HCl (half maximal inhibitory concentration, IC 50 = 2.8 nmol/L and > 3500-fold selectivity) exhibiting desirable solubility and metabolic stability with a remarkable bioavailability of 50% was identified with the aid of efficient methods of binding free energy predictions. Animal PAH studies showed that the improvement offered by 14· 3HCl [2.5 mg/kg, oral administration (p.o.)] was comparable to tadalafil (5.0 mg/kg, p.o.), verifying the feasibility of PDE10A inhibitors for the anti-PAH treatment. The crystal structure of the PDE10A− 14 complex illustrates their binding pattern, which provided a guideline for rational design of highly selective PDE10A inhibitors. A potent and highly selective PDE10A inhibitor, 14 ·3HCl (IC 50 = 2.8 nmol/L and > 3500-folds selectivity) with a remarkable bioavailability of 50% was obtained to verify the feasibility for the anti-PAH treatment. The crystal structure of PDE10A– 14 complex illustrated the binding pattern, providing a guideline for rational design of highly selective PDE10A inhibitors. Image 1 [ABSTRACT FROM AUTHOR]